Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2020-06-09 Regulatory Filings
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Nghị quyết HĐQT số 31 ngày 09/06/2020
Regulatory Filings Classification · 74% confidence The document is a regulatory “Công bố thông tin” filing to the State Securities Commission and the Ho Chi Minh Stock Exchange. It discloses a Board of Directors resolution (Nghị quyết HĐQT) appointing PwC Vietnam as the independent auditor and authorizing the CEO to sign the audit contract. This is not a full audit report or annual report, nor is it a change in board members. It’s an official regulatory announcement providing an attached board resolution. Therefore it falls into the general “Regulatory Filings” category (RNS).
2020-06-09 Vietnamese
IMP: Báo cáo kết quả giao dịch cổ phiếu của người nội bộ Lê Thị Kim Chung
Director's Dealing Classification · 95% confidence The document is a formal report to the securities commission and stock exchange detailing the number, series, and timing of share transactions by an insider (Lê Thị Kim Chung) in the public company Imexpharm. It lists pre-transaction holdings, shares traded, post-transaction holdings, transaction method, and period. This matches the definition of an insider personal share transaction report (Director’s Dealing).
2020-06-05 Vietnamese
IMP: Báo cáo kết quả giao dịch cổ phiếu của người có liên quan đến người nội bộ Hoàng Thị Huệ
Director's Dealing Classification · 90% confidence The document is a Vietnamese insider trading report (“ĐẢO CÁO KẾT QUẢ GIAO DỊCH CỔ PHIẾU … CỦA NGƯỜI NỘI BỘ”), detailing personal share transactions by a company insider. This aligns with the Director’s Dealing category.
2020-06-05 Vietnamese
IMP: Nghị quyết HĐQT về phương án trả cổ tức và thưởng cổ phiếu
Share Issue/Capital Change Classification · 95% confidence The document is a corporate disclosure of a Board of Directors resolution detailing the issuance of new shares to pay dividends in cash and stock, bonus share issuance, and the related increase in charter capital along with registration for additional listing on the stock exchange. This falls squarely under announcements of capital changes/share issues, matching the definition for Share Issue/Capital Change (SHA).
2020-06-03 Vietnamese
IMP: Link công bố Điều lệ và Quy chế quản trị công ty
Report Publication Announcement Classification · 80% confidence The document is a short regulatory disclosure to the State Securities Commission and Stock Exchange announcing that the Company’s Charter and internal corporate governance regulations were approved at the AGM and are now available via links on the company website. It does not contain the actual Charter or governance content, only a publication notice. Under the “menu vs meal” rule, this is an announcement of report publication rather than the report itself.
2020-06-03 Vietnamese
IMP: Báo cáo về ngày không còn là cổ đông lớn Balestrand Limited
Major Shareholding Notification Classification · 85% confidence The document is a formal notice by an institutional investor (Balestrand Limited) to regulatory bodies reporting its reduction of shareholding in Imexpharm from above 5% down to 0%, thereby ceasing to be a major shareholder. This is a change in significant share ownership crossing regulatory thresholds rather than a company’s self-share transaction. It fits the definition of a Major Shareholding Notification (MRQ).
2020-06-03 Tagalog

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.